Design-encoded dual shape-morphing and shape-memory in 4D printed polymer parts toward cellularized vascular grafts.

Current additive manufacturing technologies wherein as-printed simple two-dimensional (2D) structures morph into complex tissue mimetic three-dimensional (3D) shapes are limited to multi-material hydrogel systems, which necessitates multiple fabrication steps and specific materials. This work utilizes a single shape memory thermoplastic polymer (SMP), PLMC (polylactide-co-trimethylene carbonate), to achieve programmable shape deformation through anisotropic design and infill angles encoded during 3D printing. The shape changes were first computationally predicted through finite element analysis (FEA) simulations and then experimentally validated through quantitative correlation. Rectangular 2D sheets could self-roll into complete hollow tubes of specific diameters (ranging from ≈6 mm to ≈10 mm) and lengths (as long as 40 mm), as quantitatively predicted from FEA simulations within one minute at relatively lower temperatures (≈80 °C). Furthermore, shape memory properties were demonstrated post-shape change to exhibit dual shape morphing at temperatures close to physiological levels. The tubes (retained as the permanent shape) were deformed into flat sheets (temporary shape), seeded with endothelial cells (at T < Tg), and thereafter triggered at ≈37 °C back into tubes (permanent shape), utilizing the shape memory properties to yield bioresorbable tubes with cellularized lumens for potential use as vascular grafts with improved long-term patency. Additionally, out-of-plane bending and twisting deformation were demonstrated in complex structures by careful control of infill angles that can unprecedently expand the scope of cellularized biomimetic 3D shapes. This work demonstrates the potential of the combination of shape morphing and SMP behaviors at physiological temperatures to yield next-generation smart implants with precise control over dimensions for tissue repair and regeneration.

Pressure-Spun Fibrous Surgical Sutures for Localized Antibacterial Delivery: Development, Characterization, and In Vitro Evaluation.

Surgical sutures designed to prevent infection are critical in addressing antibiotic-resistant pathogens that cause surgical site infections. Instead of antibiotics, alternative materials such as biocides have been assessed for coating commercially used sutures due to emerging antibiotic resistance concerns worldwide. This study has a new approach to the development of fibrous surgical sutures with the ability to deliver localized antibacterial agents. A new manufacturing process based on pressure spinning was used for the first time in the production of fibrous surgical sutures by physically blending antibacterial triclosan (Tri) agent with poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene oxide) (PEO) polymers. Fibrous surgical sutures with virgin PLGA, virgin PEO, different ratios of PLGA-PEO, and different ratios of Tri-loaded PLGA-PEO fibrous sutures were produced to mimic the FDA- and NICE-approved PLGA-based sutures available in the market and compared for their characteristics. They were also tested simultaneously with commercially available sutures to compare their in vitro biodegradation, antibacterial, drug release, and cytotoxicity properties. After in vitro antibacterial testing for 24 h, sutures having 285 ± 12 µg/mg Tri loading were selected as a model for further testing as they exhibited antibacterial activity against all tested bacteria strains. The selected model of antibacterial fibrous sutures exhibited an initial burst of Tri release within 24 h, followed by a sustained release for the remaining time until the sutures completely degraded within 21 days. The cell viability assay showed that these surgical sutures had no cytotoxic effect on mammalian cells.

Emerging trends in biliary stents: a materials and manufacturing perspective.

Biliary stent technology has come a long way since its inception. There have been significant advancements in the materials used, and design and deployment strategies. Options have expanded from plastic and metallic stents to a wider variety of materials and manufacturing technologies to offer several options to clinicians, including self-expandable metallic stents and bioresorbable stents. Bioresorbable biliary stents are still in the early stages of clinical adoption. This review encompasses the materials currently used for biliary stents and the significant developments in the past few years in the resorbable materials for use as biliary stents. We critically discuss the emerging trends in the development of new resorbable materials for fabricating biliary stents. We then assess the developments in drug-eluting stents and advanced manufacturing technologies that could be leveraged for biliary stents. Challenges in the paths for translation for the future, such as pre-clinical and clinical trials, are highlighted. Finally, we present future directions that could drive the biliary stent market to meet the increasingly complex and diverse clinical needs of patients.

Facile One-Pot Method for All Aqueous Green Formation of Biocompatible Silk Fibroin-Poly(Ethylene Oxide) Fibers for Use in Tissue Engineering.

Silk fibroin (SF) fibers are highly regarded in tissue engineering because of their outstanding biocompatibility and tunable properties. A challenge remains in overcoming the trade-off between functioning and biocompatible fibers and the use of cytotoxic, environmentally harmful organic solvents in their processing and formation. The aim of this research was to produce biocompatible SF fibers without the use of cytotoxic solvents, via pressurized gyration (PG). Aqueous SF was blended with poly(ethylene oxide) (PEO) in ratios of 80:20 (labeled SF-PEO 80:20) and 90:10 (labeled SF-PEO 90:10) and spun into fibers using PG, assisted by a range of applied pressures and heat. Pure PEO (labeled PEO-Aq) and SF solubilized in hexafluoro-isopropanol (HFIP) (labeled SF-HFIP) and aqueous SF (labeled SF-Aq) were also prepared for comparison. The resulting fibers were characterized using SEM, TGA, and FTIR. Their in vitro cell behavior was analyzed using a Live/Dead assay and cell proliferation studies with the SaOS-2 human bone osteosarcoma cell line (ATCC, HTB-85) and human fetal osteoblast cells (hFob) (ATCC, CRL-11372) in 2D culture conditions. Fibers in the micrometer range were successfully produced using SF-PEO blends, SF-HFIP, and PEO-Aq. The fiber thickness ranged from 0.71 ± 0.17 µm for fibers produced using SF-PEO 90:10 with no applied pressure to 2.10 ± 0.78 µm for fibers produced using SF-PEO 80:10 with 0.3 MPa applied pressure. FTIR confirmed the presence of SF via amide I and amide II bands in the blend fibers because of a change in structural conformation. No difference was observed in thermogravimetric properties among varying pressures and no significant difference in fiber diameters for pressures. SaOS-2 cells and hFOb cell studies demonstrated higher cell densities and greater live cells on SF-PEO blends when compared to SF-HFIP. This research demonstrates a scalable and green method of producing SF-based constructs for use in bone-tissue engineering applications.

Co-Axial Gyro-Spinning of PCL/PVA/HA Core-Sheath Fibrous Scaffolds for Bone Tissue Engineering.

The present study aspires towards fabricating core-sheath fibrous scaffolds by state-of-the-art pressurized gyration for bone tissue engineering applications. The core-sheath fibers comprising dual-phase poly-ε-caprolactone (PCL) core and polyvinyl alcohol (PVA) sheath are fabricated using a novel "co-axial" pressurized gyration method. Hydroxyapatite (HA) nanocrystals are embedded in the sheath of the fabricated scaffolds to improve the performance for application as a bone tissue regeneration material. The diameter of the fabricated fiber is 3.97 ± 1.31 µm for PCL-PVA/3%HA while pure PCL-PVA with no HA loading gives 3.03 ± 0.45 µm. Bead-free fiber morphology is ascertained for all sample groups. The chemistry, water contact angle and swelling behavior measurements of the fabricated core-sheath fibrous scaffolds indicate the suitability of the structures in cellular activities. Saos-2 bone osteosarcoma cells are employed to determine the biocompatibility of the scaffolds, wherein none of the scaffolds possess any cytotoxicity effect, while cell proliferation of 94% is obtained for PCL-PVA/5%HA fibers. The alkaline phosphatase activity results suggest the osteogenic activities on the scaffolds begin earlier than day 7. Overall, adaptations of co-axial pressurized gyration provides the flexibility to embed or encapsulate bioactive substances in core-sheath fiber assemblies and is a promising strategy for bone healing.

Polymer-Magnetic Composite Fibers for Remote-Controlled Drug Release.

An efficient method is reported, for the fabrication of composite microfibers that can be magnetically actuated and are biocompatible, targeting controlled drug release. Aqueous solutions of polyvinyl alcohol, incorporated with citric acid-coated Fe3O4 magnetic nanoparticles (MNPs), are subject to infusion gyration to generate 100-300 nm diameter composite fibers, with controllable MNP loading. The fibers are stable in polar solvents, such as ethanol, and do not show any leaching of MNPs for over 4 weeks. Using acetaminophen as an example, we demonstrate that this material is effective in immobilization and triggered release of drugs, which is achieved by a moving external magnetic field. The remote actuation ability, coupled with biocompatibility and lightweight property, renders enormous potential for these fibers to be used as a smart drug release agent.

Tissue engineering small-diameter vascular grafts: preparation of a biocompatible porcine ureteric scaffold.

This study aimed to investigate a biocompatible, biomechanically functional, small-diameter (<6 mm) scaffold for tissue engineering a vascular graft using acellular porcine ureters. Porcine ureters were decellularized and sterilized using sequential treatment with hypotonic Tris buffer, sodium dodecyl sulphate 0.1% w/v (plus proteinase inhibitors), nuclease solution (RNase and DNase), and peracetic acid. The scaffold was compared with fresh ureter according to histology, immunocytochemistry, quantitative determination of alpha-galactosyl (alpha-Gal), and biochemistry. The biomechanical properties of the scaffold were compared with those of fresh ureters and human saphenous vein. The biocompatibility of decellularized ureters was assessed using in vitro contact and extract cytotoxicity tests. The in vivo biocompatibility was investigated using a mouse model. The histioarchitecture of the acellular ureteric scaffolds was preserved with some loss of basement membrane proteins while showing no evidence of cellularity. There was no evidence of residual alpha-Gal epitope present in acellular ureter. The ultimate tensile strength, compliance, and burst pressures of the acellular ureters were not compromised, compared with fresh tissues (p > 0.05), and the results compared favorably with fresh human saphenous vein samples (p > 0.05). The decellularized scaffolds were shown to be biocompatible with porcine smooth muscle and endothelial cells in vitro. One month after subcutaneous implantation in mice, explants were analyzed immunohistochemically using anti-CD3, Factor VIII, F4/80 (macrophage), and alpha-smooth muscle actin antibodies. The fresh tissue controls had a significantly thicker capsule (of inflammatory cells and fibrous tissue) than decellularized implants (p < 0.05). Decellularized explants were infiltrated with a combination of fibroblast-like cells and macrophages, indicating a healthy repair process. This study has demonstrated the potential of acellular porcine ureteric scaffolds in tissue engineering small-diameter living vascular grafts.